<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/869F0B29-11C9-4722-9E9E-205F6BC4F56D"><gtr:id>869F0B29-11C9-4722-9E9E-205F6BC4F56D</gtr:id><gtr:name>Tecan UK Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/33735849-D455-4914-AB52-D4E0A8F67091"><gtr:id>33735849-D455-4914-AB52-D4E0A8F67091</gtr:id><gtr:name>Pluriomics BV</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/42B56A32-9194-468C-A790-BE55133838A6"><gtr:id>42B56A32-9194-468C-A790-BE55133838A6</gtr:id><gtr:name>University of Hamburg</gtr:name><gtr:address><gtr:line1>ZMK</gtr:line1><gtr:line2>Blunderstrasse</gtr:line2><gtr:line4>Hamburg</gtr:line4><gtr:line5>20146</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A0164CD1-D64C-4811-88B8-67B800E02651"><gtr:id>A0164CD1-D64C-4811-88B8-67B800E02651</gtr:id><gtr:name>Tokyo Electron</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/869F0B29-11C9-4722-9E9E-205F6BC4F56D"><gtr:id>869F0B29-11C9-4722-9E9E-205F6BC4F56D</gtr:id><gtr:name>Tecan UK Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/33735849-D455-4914-AB52-D4E0A8F67091"><gtr:id>33735849-D455-4914-AB52-D4E0A8F67091</gtr:id><gtr:name>Pluriomics BV</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/42B56A32-9194-468C-A790-BE55133838A6"><gtr:id>42B56A32-9194-468C-A790-BE55133838A6</gtr:id><gtr:name>University of Hamburg</gtr:name><gtr:address><gtr:line1>ZMK</gtr:line1><gtr:line2>Blunderstrasse</gtr:line2><gtr:line4>Hamburg</gtr:line4><gtr:line5>20146</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0164CD1-D64C-4811-88B8-67B800E02651"><gtr:id>A0164CD1-D64C-4811-88B8-67B800E02651</gtr:id><gtr:name>Tokyo Electron</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6D93C4B4-6A1A-4858-8A69-03438AAFF1FC"><gtr:id>6D93C4B4-6A1A-4858-8A69-03438AAFF1FC</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Denning</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A398B4B7-4241-4DF2-832E-097103A0A371"><gtr:id>A398B4B7-4241-4DF2-832E-097103A0A371</gtr:id><gtr:firstName>Lorraine</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Young</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FG010390%2F1"><gtr:id>10D2863B-5076-4627-9834-07974881AC1D</gtr:id><gtr:title>Developing scalable and standardised manufacturing methods for human pluripotent stem cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/G010390/1</gtr:grantReference><gtr:abstractText>So that people can live longer and more active lives there is a need to develop new affordable and effective medicines. In some cases cells that we have within our own bodies can be used to repair damaged tissues. However, in adults, this repair mechanism is very limited and often inefficient. The cells that make up the very early developing embryo are those that can go on to make all of the cells in the human body and these so called 'stem cells' when harvested from embryos have the potential to repair many types of diseased tissue in adults. Although stem cells from embryos can now be grown in laboratories, one highly trained person can only grow a few million cells in a week. Since it takes 5 billion heart cells to repair the heart muscle of a heart-attack patient, growing these cells manually is useful for research but not for treating multiple patients in practise. This project aims to combine the expertise of both stem cell scientists and engineers, to create large-scale systems for the 'manufacture' of large numbers of stem cells so the potential of stem cell therapies can be realised. This is not a trivial task since the way we culture stem cells manually is very different from those grown in 'factories'. Therefore this project will identify the parts of the manual cell culture process that need to be improved for the large scale cost effective manufacture of stem cells for therapeutic purposes. Once enough stem cells can be routinely grown and harvested, it is more likely that they can be made into enough heart, nerve and pancreas cells to begin to treat disease.</gtr:abstractText><gtr:technicalSummary>Pluripotent hESCs are a major emerging platform for a wide range of therapeutic cell based products and pharmaceutical assays, however there are major barriers to their commercial-scale production. Our multidisciplinary collaboration will improve the understanding and reliability of cell expansion for pluripotent human embryonic stem (hESC) and induced pluripotency (hIPSC) cells by: 1) investigating properties of pluripotent cells that influence their processing and scale-up using our experience of multiple cell lines and culture conditions to scope generic process conditions 2) optimising and validating automated bioprocess protocols to enable robust and reproducible manufacture of hESC-based products at commercial scales. To maximise the range of manufacturing scales that are likely to be required for e.g. pharmaceutical screening processes or regenerative medicine applications, we will develop medium scale (entirely automated 90 X T175 flask T-flask culture in the CompacT SelecT) and larger scale (for potentially up to 1000L bioreactor) systems in parallel, using the same source of highly characterised cells. The processes that we deliver will have improved cost-effectiveness over current systems and will allow standardised culture protocols to be applied to multiple human pluripotent cell lines. Statistically-designed factorial experiments, underpinned by systematic process improvement, will identify the variables in manual culture methods that affect the practicality of scaled hESC manufacture. Factorial experimentation &amp;amp; quality optimisation (biological function, variation &amp;amp; cost) of the bioprocessed cell product will be achieved through gaining an understanding of all relevant variables through a unique collaboration between stem cell biologists and bioprocess/biomanufacturing engineers.</gtr:technicalSummary><gtr:fund><gtr:end>2012-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-02-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>363001</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tecan UK Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Automation (Development of robot)</gtr:description><gtr:id>AE1EEC3A-9A08-4AEE-A906-AE582F5E652F</gtr:id><gtr:impact>Publications, grants</gtr:impact><gtr:partnerContribution>Role in automation</gtr:partnerContribution><gtr:piContribution>Bespoke robotic platform for automated culture and differentiation of human stem cells</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC-TEL consortium (Manchester, UKSCB, Sanger, TEL)</gtr:description><gtr:id>0BA04CCC-5AFD-47C7-9965-DA31395292E3</gtr:id><gtr:impact>joint grant with industrial partner</gtr:impact><gtr:partnerContribution>joint grant with industrial partner</gtr:partnerContribution><gtr:piContribution>joint grant with industrial partner</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Safety Assessment GSK</gtr:department><gtr:description>Industrial collaboration (GSK via CRACK-IT)</gtr:description><gtr:id>24E88897-3E85-4FAA-96FA-62D04636EECF</gtr:id><gtr:impact>Financial, international collaboration, skills sharing, joint PhD students, researcher exchange</gtr:impact><gtr:partnerContribution>Implicit in the sponsorship and construction of the challenge</gtr:partnerContribution><gtr:piContribution>Facilitated award of NC3Rs CRACK-IT grant</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>CRACK-IT consortium</gtr:description><gtr:id>D17D3D80-5900-4B81-8651-2C4DB66972C2</gtr:id><gtr:impact>publications and grants</gtr:impact><gtr:partnerContribution>all active contributors to researcher and academic input</gtr:partnerContribution><gtr:piContribution>consortium working on safety assessment</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy Nottingham</gtr:department><gtr:description>surface work (Morgan Alexander, Nottingham)</gtr:description><gtr:id>887B95C2-1A5D-41EF-B9C5-C92D69F5C61C</gtr:id><gtr:impact>grants and papers</gtr:impact><gtr:partnerContribution>Multiple grant awards and papers</gtr:partnerContribution><gtr:piContribution>lead the stem cell work of this collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Syngenta</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>syngenta</gtr:description><gtr:id>79290876-D812-439D-8E93-37B1F9D1B20F</gtr:id><gtr:impact>advances in stem cell automation</gtr:impact><gtr:partnerContribution>intellectual and financial input</gtr:partnerContribution><gtr:piContribution>stem cell automation</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technion - Israel Institute of Technology</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:description>BIRAX interactions (Mummery, Gepstein)</gtr:description><gtr:id>5891FF21-5819-40E7-9A68-D9F7900E293C</gtr:id><gtr:impact>Early stage at present</gtr:impact><gtr:partnerContribution>Skills in progenitor cell biology and cell transplantation in vivo</gtr:partnerContribution><gtr:piContribution>New partnership between three labs</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Institute for Biological Standards and Control (NIBSC)</gtr:department><gtr:description>MRC-TEL consortium (Manchester, UKSCB, Sanger, TEL)</gtr:description><gtr:id>8D4BFA6C-5C96-4981-AC43-D3C6C21240A1</gtr:id><gtr:impact>joint grant with industrial partner</gtr:impact><gtr:partnerContribution>joint grant with industrial partner</gtr:partnerContribution><gtr:piContribution>joint grant with industrial partner</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hamburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>CRACK-IT consortium</gtr:description><gtr:id>ABC3DCA6-F366-43BA-A0A6-D510C3338E30</gtr:id><gtr:impact>publications and grants</gtr:impact><gtr:partnerContribution>all active contributors to researcher and academic input</gtr:partnerContribution><gtr:piContribution>consortium working on safety assessment</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC-TEL consortium (Manchester, UKSCB, Sanger, TEL)</gtr:description><gtr:id>C41CDCD5-E447-4720-B4BE-B024BCB0C3A5</gtr:id><gtr:impact>joint grant with industrial partner</gtr:impact><gtr:partnerContribution>joint grant with industrial partner</gtr:partnerContribution><gtr:piContribution>joint grant with industrial partner</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Safety Assessment GSK</gtr:department><gtr:description>CRACK-IT consortium</gtr:description><gtr:id>E2083922-97ED-4975-B330-0512E7B9D495</gtr:id><gtr:impact>publications and grants</gtr:impact><gtr:partnerContribution>all active contributors to researcher and academic input</gtr:partnerContribution><gtr:piContribution>consortium working on safety assessment</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London (QMUL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Queen Mary College</gtr:department><gtr:description>Electrophysiology mechanisms (Harmer / Tinker)</gtr:description><gtr:id>5749E698-819D-48EF-B77B-02899F83C70A</gtr:id><gtr:impact>grants awarded. Papers in progress</gtr:impact><gtr:partnerContribution>Skills in detailed electrophyioslogy</gtr:partnerContribution><gtr:piContribution>mechanism of electrophysiology in hPSC-cardiomyocytes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CRACK-IT consortium</gtr:description><gtr:id>337B9A35-3135-4B10-BCD9-7083621190C9</gtr:id><gtr:impact>publications and grants</gtr:impact><gtr:partnerContribution>all active contributors to researcher and academic input</gtr:partnerContribution><gtr:piContribution>consortium working on safety assessment</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pluriomics BV</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>CRACK-IT consortium</gtr:description><gtr:id>0293EF69-6CB8-4EDD-9D29-4AE5900ECEF2</gtr:id><gtr:impact>publications and grants</gtr:impact><gtr:partnerContribution>all active contributors to researcher and academic input</gtr:partnerContribution><gtr:piContribution>consortium working on safety assessment</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tokyo Electron</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>MRC-TEL consortium (Manchester, UKSCB, Sanger, TEL)</gtr:description><gtr:id>6C9ED69D-B1FD-46CF-A2E2-2A342A99CD05</gtr:id><gtr:impact>joint grant with industrial partner</gtr:impact><gtr:partnerContribution>joint grant with industrial partner</gtr:partnerContribution><gtr:piContribution>joint grant with industrial partner</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Various presentations that Lisa, Yan and Roger did for BBSRC projects</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>55F43D36-E70C-46B6-95B1-6F6750B66CC3</gtr:id><gtr:impact>Presentations, workshops, posters, industrial engagement</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asha E-term fellowship</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>A2C26CF2-55D1-403E-965E-226E7297DCE7</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>115000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC equip - seahorse</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>E09A580F-76F7-4C3A-9772-FB41D92A64EB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3Rs-CRACK-IT phase 2</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>A28D4861-2EE4-453E-875D-3F727AE5B826</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF MyoD grant</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/14/59/31000</gtr:fundingRef><gtr:id>F6633788-FBEC-411D-A544-9DA46A94DD96</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Centre for Regen Med</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>P47352/</gtr:fundingRef><gtr:id>2CEF0866-CA89-44E3-8421-23EDC14F41BE</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>? MRC grant MR/M017354/1: MICA: Development of Metrics and Quality Standards for Scale up of Human Pluripotent Stem Cells. 1.5.15-30.4.17 &amp;pound;1.</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M017354/1</gtr:fundingRef><gtr:id>8A1B7B03-FC2F-4F14-B794-928FE3FD1841</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>475000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Programme Grant (2 pilot with Sian Harding)</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>RG/11/19/29264</gtr:fundingRef><gtr:id>AD7708D1-5FB6-4409-AFF7-AB4723240467</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>714000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC capital equipment</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L012618/1</gtr:fundingRef><gtr:id>57D5A13D-4517-4D24-B063-485DD2C0822A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>147000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Heart Res UK (Divya)</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Heart Research UK</gtr:fundingOrg><gtr:fundingRef>TRP01/12</gtr:fundingRef><gtr:id>2C14FB88-7D64-4DCD-88C0-788451AF3559</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>? BHF Special Project no. SP/15/9/31605. &amp;quot;Coupling gene targeted reporters with fully automated compound library screening to mature hPSC-cardiomyocytes&amp;quot;.</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>SP/15/9/31605</gtr:fundingRef><gtr:id>B39E04F1-79DC-45FD-AECA-92DACBC19D4D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>67000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>? EPSRC Impact Accelerator Award. A Strategic Partnership with the Australian Cooperative Research Centre for Cell Therapy Manufacturing (CRC-CTM) to Commercialise Stem Cell Culture Polymers</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>n/a</gtr:fundingRef><gtr:id>37E6A7F2-A7C4-4B39-B1E3-7436B0E3C043</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>515000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3Rs main panel (Viola)</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:fundingRef>NC/K000225/1</gtr:fundingRef><gtr:id>7B1290F8-FC2D-496E-B996-7D93E6631F03</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>? BIRAX grant 04BX14CDLG. Gene targeted optogenetics in hPSC-cardiovascular cells for transplantation into animal models of heart dysfunction. 1.9.15-31.8.18. &amp;pound;400K</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>British Council</gtr:fundingOrg><gtr:fundingRef>04BX14CDLG</gtr:fundingRef><gtr:id>D96CD27E-7A60-4593-A872-B6499719AAE2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>? BHF Programme Grant RG/15/6/31436: Predicting anti-arrhythmic drug efficacy from the divergent molecular basis of RyR2 dysfunction in genetic arrhythmia syndromes</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>RG/15/6/31436</gtr:fundingRef><gtr:id>55A4A6F7-D1B5-4B4B-BBD2-D7A274852E69</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>? EPSRC Programme Grant EP/N006615/1: 'Next Generation Biomaterials Discovery'. PI: Morgan Alexander. Multiple Co-Is. 1.10.15-30.9.20. &amp;pound;6.6m</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/N006615/1</gtr:fundingRef><gtr:id>AE4F0382-F90B-47F6-B8C3-6E310337A1D3</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3Rs-CRACK-IT phase 1</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>930EAB14-10FC-43D0-BD0A-62788F5B0C74</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU - dave</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>DB38EFA6-F4B1-44F7-B7A2-9C6C770472EE</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF programme 2014-17</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>C761E2D6-69DB-450C-95A9-900520AFAD8E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>602000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Nottingham Strategic Development Fund &amp;quot;Nottingham Regenerative Medicine Centre&amp;quot; 1.1.15-31.12.18. &amp;pound;602,140 (PI)</gtr:description><gtr:end>2020-10-02</gtr:end><gtr:fundingOrg>University of Nottingham</gtr:fundingOrg><gtr:fundingRef>n/a</gtr:fundingRef><gtr:id>D03C3E78-A8D2-4D7A-B4BE-964BAD96C5BC</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>These have been submitted previously to BBSRC. However, I do not have access to them as I was not PI on the grant - I am covering this return for a colleague who left the University 2 years ago</gtr:description><gtr:firstYearOfImpact>2011</gtr:firstYearOfImpact><gtr:id>3D703418-6911-4151-A70D-9F8BBFED7BB9</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Assisted with establishment of robotic platforms for stem cell culture and differentiation</gtr:description><gtr:exploitationPathways>We continued to develop the robotic platforms ourselves, which has been successful for publication and securing further funding</gtr:exploitationPathways><gtr:id>18951CC5-05FC-424B-9072-3FEDCC515579</gtr:id><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/946C7C87-3BB8-4CD6-AEF7-CDFD3D088D64"><gtr:id>946C7C87-3BB8-4CD6-AEF7-CDFD3D088D64</gtr:id><gtr:title>Identification of polymer surface adsorbed proteins implicated in pluripotent human embryonic stem cell expansion.</gtr:title><gtr:parentPublicationTitle>Biomaterials science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12624f7c7748d454dbff9720d6c307a4"><gtr:id>12624f7c7748d454dbff9720d6c307a4</gtr:id><gtr:otherNames>Hammad M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2047-4830</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55626BEA-07F8-4561-BB22-EC89FE298894"><gtr:id>55626BEA-07F8-4561-BB22-EC89FE298894</gtr:id><gtr:title>Exon skipping and gene transfer restore dystrophin expression in hiPSC-cardiomyocytes harbouring DMD mutations.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0a82c1753617d519e42ca31d6631d0a"><gtr:id>d0a82c1753617d519e42ca31d6631d0a</gtr:id><gtr:otherNames>Dick E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/345A10A5-5ADC-4B98-BDCB-EDD35D7A850A"><gtr:id>345A10A5-5ADC-4B98-BDCB-EDD35D7A850A</gtr:id><gtr:title>Current status of drug screening and disease modelling in human pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>BioEssays : news and reviews in molecular, cellular and developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/295ffa75c27b1791106e9b65b0baa8fc"><gtr:id>295ffa75c27b1791106e9b65b0baa8fc</gtr:id><gtr:otherNames>Rajamohan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0265-9247</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8A0EBCCE-EFD8-4AAE-8905-1037320D954A"><gtr:id>8A0EBCCE-EFD8-4AAE-8905-1037320D954A</gtr:id><gtr:title>Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1dc533ec61bcb06d365d185e0dabeb1f"><gtr:id>1dc533ec61bcb06d365d185e0dabeb1f</gtr:id><gtr:otherNames>Denning C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9128956C-83ED-4142-BB4A-4ADA7AD8AD68"><gtr:id>9128956C-83ED-4142-BB4A-4ADA7AD8AD68</gtr:id><gtr:title>Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c737bf77ff2d19310dc6d3e68481b0fd"><gtr:id>c737bf77ff2d19310dc6d3e68481b0fd</gtr:id><gtr:otherNames>Matsa E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C915F382-05B0-46D6-B0EC-49FDBB315886"><gtr:id>C915F382-05B0-46D6-B0EC-49FDBB315886</gtr:id><gtr:title>Discovery of a Novel Polymer for Human Pluripotent Stem Cell Expansion and Multilineage Differentiation.</gtr:title><gtr:parentPublicationTitle>Advanced materials (Deerfield Beach, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/71778760bcfbaedc02a6e2939f7135ca"><gtr:id>71778760bcfbaedc02a6e2939f7135ca</gtr:id><gtr:otherNames>Celiz AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0935-9648</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/728E5E1C-78CF-4EE1-8B9E-AA3698B9CAD9"><gtr:id>728E5E1C-78CF-4EE1-8B9E-AA3698B9CAD9</gtr:id><gtr:title>In vitro uses of human pluripotent stem cell-derived cardiomyocytes.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular translational research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c737bf77ff2d19310dc6d3e68481b0fd"><gtr:id>c737bf77ff2d19310dc6d3e68481b0fd</gtr:id><gtr:otherNames>Matsa E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1937-5387</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/498EE3EA-A7A3-4387-8C5F-701039740B43"><gtr:id>498EE3EA-A7A3-4387-8C5F-701039740B43</gtr:id><gtr:title>Scaling human pluripotent stem cell expansion and differentiation: are cell factories becoming a reality?</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3ee80f93fb699e3ce06d44043a7ef99d"><gtr:id>3ee80f93fb699e3ce06d44043a7ef99d</gtr:id><gtr:otherNames>Smith JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B01D24B-8414-46F6-9DE1-70282425F55E"><gtr:id>1B01D24B-8414-46F6-9DE1-70282425F55E</gtr:id><gtr:title>A defined synthetic substrate for serum-free culture of human stem cell derived cardiomyocytes with improved functional maturity identified using combinatorial materials microarrays.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/15f5a65ec20558965fa2d27363b8d946"><gtr:id>15f5a65ec20558965fa2d27363b8d946</gtr:id><gtr:otherNames>Patel AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/G010390/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>